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Objective: Patients with schizophrenia often experience comorbid obsessive-compulsive symptoms. Within these
patients, a significant subgroup developed secondary obsessive-compulsive symptoms during treatment with
clozapine.
Method: In this paper, we report on four cases in which adjunctive therapy with aripiprazole was tested to alleviate
obsessive-compulsive symptoms in schizophrenia.
Results: All four patients had a significant improvement in obsessive-compulsive symptoms. The combination of
clozapine and aripiprazole was well tolerated.
Conclusion: This case series demonstrates the clinical efficacy of aripiprazole adjunctive therapy with clozapine in
schizophrenic patients with comorbid obsessive-compulsive symptoms. Larger-sampled and controlled studies are
required in order to test and confirm these observations.
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The incidence of obsessive-compulsive symptoms (OCS)
in schizophrenia had been reported as 20–30% [1]. Pub-
lications related to exacerbation of the OCS in patients
with schizophrenia by atypical antipsychotics focused on
the mechanism of action of these drugs [2].
The striatal 5-HT2 antagonism of new-generation an-
tipsychotics may result in the emergence of OCS via an
overactive dopaminergic system. The weak D2 receptor-
blocking properties of clozapine may be also accounted
for the onset of OCD-like symptoms [3]. Temporary
OCS is associated with the dose of clozapine reported in
the literature [4]. A total of 55 patients are included in
30 reports between 1990 and 2002, focusing on atypical
antipsychotic treatment-induced OCS or exacerbation of
preexisting OCS in patients with schizophrenia. Of these
patients, 30 developed OCS with the use of clozapine,
16 with risperidone, 8 with olanzapine, and 1 with que-
tiapine [5]. In a study of 50 patients with a diagnosis of
schizophrenia treated with clozapine, 10 of the subjects
developed OCS after clozapine treatment and 9 patients* Correspondence: gokben.hizlisayar@uskudar.edu.tr
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reproduction in any medium, provided the orhad an increase in preexisting OCS [6]. In treatment re-
sistant of schizophrenia, the first-line treatment option is
clozapine but with the dose escalation, the risk of trig-
gering OCS and need for adjunctive therapy arises [7,8].
This study summarizes the courses of four patients
with schizophrenia who experienced OCS under treat-
ment with clozapine so dose escalation of clozapine
could not be done and need for augmentation therapy
arises. The effects of aripiprazole and clozapine combin-
ation on OCS and psychotic symptoms are presented.Cases
Case 1
A 51-year-old, Caucasian, male patient, diagnosed with
schizophrenia was admitted following an exacerbation of
OCS. He had contamination obsessions and cleaning
compulsions for 10 years. He had persecution delusions.
He was thinking that he was followed by police. He was
hoarding garbage. He was brought to the emergency
room by his family. Both the patient and his family re-
ported that he had benefitted most from clozapine treat-
ment. He was on clozapine 100 mg/day for 4 years.
However, when the dose of clozapine was increased to a
dose of 150 mg/day, an increase in OCS was observed.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sions of electroconvulsive therapy (ECT), his psychotic
and OCS decreased; but for the last 5–6 months, there
was an exacerbation in psychotic and obsessive symptoms.
Patient was hospitalized. During admission, his Positive
and Negative Syndrome Scale (PANSS), Brief Psychiatric
Rating Scale (BPRS), and Yale–Brown Obsessive Com-
pulsive Scale (Y-BOCS) scores were 151, 74, and 40,
respectively.
A 30-mg/day dose of aripiprazole was added on to his
ongoing 100-mg/day dose of clozapine treatment. After
2 weeks of combination treatment with 100 mg/day
clozapine and 10 mg/day aripiprazole, plasma levels of
both drugs were measured to be low. Clozapine dose in-
creased to 250 mg/day and aripiprazole doze increased
to 30 mg/day gradually. At the end of the sixth week,
during discharge, his PANSS, BPRS, and Y-BOCS scores
were 50, 20, and 20, respectively.
Case 2
A 28-year-old, Caucasian, male patient, with a diagnosis
of residual schizophrenia, treated for 2 years with cloza-
pine 100 mg/day was admitted because of the worsening
of his psychotic symptoms. His OCS first was seen at age
of 13. He had control and symmetry obsessions and com-
pulsions. After 5 years of OCS, he had psychotic symp-
toms. He reported that he could not leave the house forTable 1 The clinical rating scale scores, doses, and plasma co
1st day 2nd week
Case 1: age 51, male 100 mg/day clozapine 100 mg/day clozapine
(90.7 ng/mL) (96.2 ng/mL)
+ +
30 mg/day aripiprazole 30 mg/day aripiprazole 3
(222.2 ng/mL)
Case 2: age 28, male 100 mg/day clozapine 200 mg/day clozapine
(142.8 ng/mL) (198.0 ng/mL)
+ +
30 mg/day aripiprazole 30 mg/day aripiprazole 3
(100.78 ng/mL)
Case 3: age 34, male 100 mg/day clozapine 150 mg/day clozapine
(52.7 ng/mL) (291.4 ng/mL)
+ +
30 mg/day aripiprazole 30 mg/day aripiprazole 1
(787 ng/mL)
Case 4: age 27, male 150 mg/day clozapine 200 mg/day clozapine
(142 ng/mL) (332 ng/mL)
+ +
30 mg/day aripiprazole 30 mg/day aripiprazole 3
(353 ng/mL)the last 2 years, due to his persecution delusions,
skepticism, and resentment. He was on a treatment of
clozapine 100 mg/day for 2 years.
He was hospitalized with a dose of 10 mg/day aripi-
prazole added on to his ongoing 100-mg/day clozapine
treatment. The plasma level of clozapine and norcloza-
pine were lower than therapeutic level at the admission.
At the end of the second week, clozapine dose increased
to 200 mg/day and aripiprazole to 30 mg/day gradually.
The clozapine, norclozapine, aripiprazole doses and the
clinical rating scale scores are given at Table 1. During
discharge, his scores of PANSS was 49 (78 at admission),
BPRS was 27 (39 at admission), and Y-BOCS was 15
(40 at admission).
Case 3
A 34-year-old, Caucasian, male patient with a diagnosis
of paranoid schizophrenia for 14 years was admitted for
psychiatric examination with complaints of repeating
some words and washing hands frequently. He was on
clozapine 100 mg/day treatment for 2 years. He was
hospitalized due to exacerbation of psychotic and OCS.
A 10-mg/day dose of aripiprazole was added on to his
ongoing 100-mg/day clozapine treatment. At the end of
the first week, clozapine dose increased to 150 mg/day
and aripiprazole dose to 30 mg/day gradually. The plasma
clozapine and norclozapine levels were over therapeuticncentrations of clozapine and aripiprazole
3rd week 4th week PANSS Y-BOCS
250 mg/day clozapine 250 mg/day clozapine Baseline Baseline
(215 ng/mL) (132.5 ng/mL) 151 40
+ + 4th week 4th week
0 mg/day aripiprazole 30 mg/day aripiprazole 50 20
(300.7 ng/mL) (322.8 ng/ml)
200 mg/day clozapine 100 mg/day clozapine Baseline Baseline
(332.7 ng/mL) (232 ng/mL) 78 40
+ + 4th week 4th week
0 mg/day aripiprazole 30 mg/day aripiprazole 49 15
(363.51 ng/mL) (368.23 ng/ml)
150 mg/day clozapine 100 mg/day clozapine Baseline Baseline
(749.1 ng/mL) (546.2 ng/mL) 141 40
+ + 4th week 4th week
5 mg/day aripiprazole 15 mg/day aripiprazole 50 20
(243 ng/mL) (310 ng/mL)
150 mg/d clozapine 100 mg/d clozapine Baseline Baseline
(241.7 ng/mL) (203.4 ng/mL) 159 30
+ + 4th week 4th week
0 mg/day aripiprazole 30 mg/day aripiprazole 46 10
(358.4 ng/mL) (347.8 ng/mL)
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week, so clozapine dose decreased to 100 mg/day. The
clozapine andaripiprazole doses, plasma drug levels, and
the clinical rating scale scores are given at Table 1. During
discharge, his scores of PANSS was 50 (141 at admission),
BPRS was 20 (74 at admission), and YBOCS was 20 (40 at
admission).
Case 4
A 27-year-old, Caucasian, male patient, diagnosed with
substance-induced psychotic disorder, was hospitalized
due to exacerbation of psychotic symptoms despite cloza-
pine dose of 150 mg/day for two years. His family reported
exacerbation of obsessive-compulsive symptoms, such as
contamination obsessions and frequent handwashing, for
3 months. Clozapine and norclozapine plasma levels were
lower than therapuetic level on admission. a 15-mg/day
aripiprazole was added on and clozapine dose increased to
200 mg/day. At the end of the first week, aripiprazole dose
was increased to 30 mg/day. Plasma clozapine and norclo-
zapine levels were found to be higher than therapeutic
level with a clozapine dose of 200 mg/day, and clozapine
dose decreased to 100 mg/day. The clozapine and aripi-
prazole doses, plasma drug levels, and the clinical rating
scale scores are given in Table 1. At the end of the fourth
week, during discharge, his scores of PANSS was 46 (159
at admission), and YBOCS was 10 (30 at admission).
Discussion
Schizophrenia is a chronic, severe, and disabling brain
disorder and affects roughly 1% of the population.
Twenty to thirty percent of the schizophrenic patients
had a partial response or no response, although they
have adequate dose and duration for the treatment of
typical and atypical antipsychotic drugs [9]. Here, we re-
port four patients with a diagnosis of schizophrenia who
benefited the clozapine treatment but due to the emer-
gence of OCS dose escalation of clozapine could not be
done. They were all treatment-resistant schizophrenic
patients and clozapine was the only effective medication
these patients responded to so far.
Although clozapine is a first-line antipsychotic treat-
ment in patients with treatment-resistant schizophrenia,
18–44% of patients who fail to respond to monotherapy
of clozapine need augmentation with a second anti-
psychotic [10]. Various researchers reported the remis-
sion of schizophrenia psychosis and strong reduction of
obsessive-compulsive disorder after adding clozapine to
aripiprazole [11,12]. The choice of aripiprazole as an ad-
junctive treatment was suggested because of its mech-
anism of action [13]. The partial dopaminergic and
serotonergic agonist aripiprazole per se was associated
with an inherent antiobsessive potency. Bachmann et al.
included 15 patients with schizophrenia from a childand adolescent psychiatric department. Patients had
been under clozapine treatment, followed by aripiprazole
augmentation. They concluded that in adolescents with
schizophrenia, aripiprazole augmentation of clozapine
treatment might be an effective therapeutic strategy
[14]. Akdag et al. reported that aripiprazole augmenta-
tion in 11 patients with a diagnosis of schizophrenia
treated for at least 6 months with clozapine resulted in
a marked improvement in 7 patients, with a diminish in
BPRS scores. Aripiprazole augmentation did not result
in any additional side effects [15]. Chanachev et al. re-
ported on two cases in which augmentation with aripi-
prazole had a beneficial impact on anxiety [16]. In a
study examining aripiprazole treatment in patients with
comorbid schizophrenia and OCS that did not meet the
full criteria for obsessive-compulsive disorder, results
suggest that aripiprazole monotherapy can modestly im-
prove the outcome for some schizophrenia patients with
obsessive-compulsive symptoms [17]. In a case study, a
patient with paranoid schizophrenia developed OCS
during long-term treatment with olanzapine at 20 mg/day
over a period of 10 years. The combination with aripipra-
zole (15 mg/day) over a period of 12 weeks resulted in a
marked improvement of OCS and some further improve-
ment of the psychotic symptoms. This observation points
toward an antiobsessive potency of aripiprazole in com-
bination with olanzapine, quite similar to approaches in-
volving clozapine [18].
It has been proposed that antiserotonergic second-
generation antipsychotics might induce OCS. Schirmbeck
et al. reported that OCS severity correlated with a dosage
of clozapine and duration of treatment [19]. It was re-
ported that reducing the dose of ‘pro-obsessive’ clozapine
by using combinations with mainly dopaminergic antipsy-
chotics might be helpful [20]. Englisch et al. reported
seven patients with schizophrenia developed second-
ary OCS during treatment with clozapine. A marked
reduction of obsessions and significant improvements
of compulsions observed after aripiprazole add-on
treatment, pointing toward an antiobsessive potency of
aripiprazole [21].
The combination of clozapine and aripiprazole had
several benefits: reduction of clozapine dose, improve-
ment of positive and negative symptoms, and reduction of
OCS. This augmentation strategy was well tolerated with
ne epileptical seizures, agranulocytosis, extrapiramidal side
effects, or cognitive side effects.
This case report's limitations include the small sample
size, non-controlled and inhomogeneous sample, pos-
sible affective course, different nature of schizophrenic
symptoms, and the high doses of aripiprazole. The rapid
improvement associated to the adjunctive treatment
with aripiprazole may also be favored by a mood en-
hancement. Aripiprazole is also a 5-H1A partial agonist,
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mood-ameliorating effects. Also, the history of previous
response to ECT may also indirectly suggest an affective
course. Unexplained relapses of the patients during cloza-
pine treatment may indicate poor medication adherence.
Conclusion
Patients suffering from clozapine-induced OCS deserve
close attention. Owing to superior antipsychotic potency
of clozapine, clinicians may not want to switch from
clozapine to another antipsychotic. It might be helpful
to reduce the dose of ‘pro-obsessive’ clozapine by using
a combination with aripiprazole. Here, our findings sug-
gest that the adjunctive use of aripiprazole with clozapine
represents a new therapeutic strategy in cases of schizo-
phrenic patients who continue to present clinically signifi-
cant obsessive-compulsive symptoms. This finding can be
proved by controlled studies; it would be of major clinical
interest.
This case report suggests that a combination of cloza-
pine and aripiprazole may optimize treatment efficacy and
tolerability in schizophrenic patients with comorbid OCS.
In the future, the proposed strategy should be further eval-
uated in prospective controlled trials.
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